ReviewAntiviral research2018
Novel activities of safe-in-human broad-spectrum antiviral agents.
Review in Antiviral research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 84 citations in OpenAlex.
- Combination of vemurafenib, pleconaril, and AG7404 attenuates enterovirus replicationNAR molecular medicine · 2026Article
- Review
- Discovery of broad-spectrum antivirals targeting viral proteases using in silico structural modeling and cellular analysis.Antiviral research · 2025Article
- Natural and Designed Cyclic Peptides as Potential Antiviral Drugs to Combat Future Coronavirus Outbreaks.Molecules (Basel, Switzerland) · 2025Review
- In Vitro Evaluation of the Antiviral Activity of Polyphenol (-)-Epigallocatechin-3-Gallate (EGCG) Against Mayaro Virus.Viruses · 2025Article
- Isolation, structural determination, and antiviral activities of a novel alanine-conjugated polyketide from Talaromyces sp.The Journal of antibiotics · 2024Article
- Article
- Review
- Combating pan-coronavirus infection by indomethacin through simultaneously inhibiting viral replication and inflammatory response.iScience · 2023Article
- An allosteric inhibitor of sirtuin 2 deacetylase activity exhibits broad-spectrum antiviral activity.The Journal of clinical investigation · 2023Article
- RETRACTED: Tyrosine Kinase Inhibitors Target B Lymphocytes.Biomolecules · 2023Article
- Bioinformatic and systems biology approach revealing the shared genes and molecular mechanisms between COVID-19 and non-alcoholic hepatitis.Frontiers in molecular biosciences · 2023Article
- Novel Synergistic Anti-Enteroviral Drug Combinations.Viruses · 2022Article
- Antiviral Activity and Mechanisms of Seaweeds Bioactive Compounds on Enveloped Viruses-A Review.Marine drugs · 2022Review
- Review
- Antiviral Activity of Approved Antibacterial, Antifungal, Antiprotozoal and Anthelmintic Drugs: Chances for Drug Repurposing for Antiviral Drug Discovery.Journal of experimental pharmacology · 2022Review
- Genomics-guided targeting of stress granule proteins G3BP1/2 to inhibit SARS-CoV-2 propagation.International journal of biological macromolecules · 2021Article
- Plant-Based Natural Products and Extracts: Potential Source to Develop New Antiviral Drug Candidates.Molecules (Basel, Switzerland) · 2021Review
- Nodosome Inhibition as a Novel Broad-Spectrum Antiviral Strategy against Arboviruses, Enteroviruses, and SARS-CoV-2.Antimicrobial agents and chemotherapy · 2021Article
- Development of remdesivir repositioning as a nucleotide analog against COVID-19 RNA dependent RNA polymerase.Journal of biomolecular structure & dynamics · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
34 authors at 13 institutions in 7 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
According to the WHO, there is an urgent need for better control of viral diseases. Re-positioning existing safe-in-human antiviral agents from one viral disease to another could play a pivotal role in this process. Here, we reviewed all approved, investigational and experimental antiviral agents, which are safe in man, and identified 59 compounds that target at least three viral diseases. We tested 55 of these compounds against eight different RNA and DNA viruses. We found novel activities for dalbavancin against echovirus 1, ezetimibe against human immunodeficiency virus 1 and Zika virus, as well as azacitidine, cyclosporine, minocycline, oritavancin and ritonavir against Rift valley fever virus. Thus, the spectrum of antiviral activities of existing antiviral agents could be expanded towards other viral diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.